Dipeptidyl peptidase 4 inhibitor improves insulin resistance in Japanese patients with type 2 diabetes: a single-arm study, a brief report.

Dipeptidyl peptidase 4 inhibitor improves insulin resistance in Japanese patients with type 2 diabetes: a single-arm study, a brief report.
复制标题

DOI:
10.1186/s13098-022-00850-9
复制
发表时间:
2022-06-07
影响因子:
4.8
通讯作者:
--
中科院分区:
医学2区
文献类型:
--
作者:

文献摘要

参考文献

被引文献

相似文献

二肽基肽酶4抑制剂(DPP 4 i)是治疗2型糖尿病(T2 DM)的有效药物。一些文献报道DPP 4 i改善胰岛素分泌和胰岛素抵抗。然而,在日本人中,葡萄糖钳夹试验和试验餐并没有很好地确定这些作用。采用葡萄糖钳夹试验和餐耐量试验(MTT)观察DPP 4 i对胰岛素抵抗和胰岛素分泌的影响。我们在8例日本T2 DM患者中进行了MTT和高胰岛素-正葡萄糖钳夹试验。本研究为单组研究。我们测量了空腹和餐后血糖、胰岛素、肠促胰岛素和胰高血糖素水平。我们还测量了血清脂联素水平。3个月后HbA 1c显著下降。空腹和餐后血糖水平显著降低。空腹和餐后胰岛素水平没有变化。葡萄糖钳夹试验的胰岛素抵抗明显改善。HOMA-IR无明显变化。GLP-1和GIP显著增加,但胰高血糖素没有变化。脂联素无明显变化。虽然患者数量很少,但这些结果表明,DPP 4 i治疗可能改善胰岛素抵抗,而不改变胰岛素分泌。
Dipeptidyl peptidase 4 inhibitor (DPP4i) is an effective medicine for type 2 diabetes mellitus (T2DM). Some articles reported DPP4i improves insulin secretion and insulin resistance. However, these effects are not well established by glucose clamp test and test meal in Japanese. We investigated the effect of DPP4i on insulin resistance and insulin secretion by using the glucose clamp test and meal tolerance test (MTT). We performed a MTT, and the hyperinsulinemic-euglycemic clamp in 8 Japanese patients with T2DM. This study was a single-arm study. We measured fasting and postprandial glucose, insulin, incretins, and glucagon levels. We also measured serum adiponectin levels. HbA1c was significantly decreased after 3 months. The fasting and postprandial glucose levels were significantly decreased. Fasting and postprandial insulin levels were not changed. The insulin resistance derived from the glucose clamp test was significantly improved. HOMA-IR was not significantly changed. GLP-1 and GIP were significantly increased but glucagon did not change. Adiponectin was not significantly changed. Although the number of patients was very small, these results suggested that DPP4i treatment might improve insulin resistance without changing insulin secretion.
DOI: 10.2337/diacare.25.11.2081
发表时间: 2002-11-01
期刊: DIABETES CARE
影响因子: 16.2
作者:
Uwaifo, GI;Fallon, EM;Yanovski, JA
通讯作者: Yanovski, JA
DOI: 10.1016/j.metabol.2006.08.004
发表时间: 2006-12-01
影响因子: 9.8
作者:
Kadowaki, Takashi;Sekikawa, Akira;Ueshima, Hirotsugu
通讯作者: Ueshima, Hirotsugu
DOI: 10.1186/1475-2840-13-96
发表时间: 2014-05-24
影响因子: 9.3
作者:
Hibuse, Toshiyuki;Maeda, Norikazu;Shimomura, Iichiro
通讯作者: Shimomura, Iichiro
DOI: 10.1371/journal.pone.0201052
发表时间: 2018
期刊: PloS one
影响因子: 3.7
作者:
Okura T;Nakamura R;Fujioka Y;Kawamoto-Kitao S;Ito Y;Matsumoto K;Shoji K;Sumi K;Matsuzawa K;Izawa S;Ueta E;Kato M;Imamura T;Taniguchi SI;Yamamoto K
通讯作者: Yamamoto K
DOI: 10.2337/dc14-2391
发表时间: 2015-01
期刊: Diabetes care
影响因子: 16.2
作者:
Hsu WC;Araneta MR;Kanaya AM;Chiang JL;Fujimoto W
通讯作者: Fujimoto W